Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure

Background β-Blocker therapy improves symptoms, left ventricular ejection fraction (LVEF), and survival in patients with congestive heart failure, but chronic effects on neurohormones have not been extensively investigated. Therefore, we examined the neurohumoral effects of carvedilol. Methods Fifty-five patients with New York Heart Association (NYHA) classes II-III congestive heart failure and LVEF ≤35% entered the study with intention to assess LVEF, NYHA class, plasma brain natriuretic peptide (BNP), N-terminal atrial natriuretic peptide (NANP), big-endothelin, endothelin-1, norepinephrine, and angiotensin II at baseline and at 6 and 12 months after initiation of carvedilol. Results Forty-six patients completed 12 months of follow-up. Left ventricular ejection fraction improved from 26% ± 8% at baseline to 39% ± 14% at 12 months. New York Heart Association class improved from 2.3 ± 0.4 at baseline to 1.8 ± 0.7 at 12 months. Brain natriuretic peptide fell from 453 ± 784 to 208 ± 393 pg/mL at 6 months and 223 ± 334 pg/mL at 12 months (P = .01 vs baseline). N-terminal atrial natriuretic peptide did not change between baseline and 6 months but fell at 12 months (2117 ± 1678, 2015 ± 1532, and 1438 ± 1442 pg/mL, respectively, P = .001 between baseline and 12 months). Angiotensin II was lower at 6 and 12 months than at baseline (12.6 ± 10, 7.8 ± 5.5 pg/mL, P < 0.001, and 11.3 ± 17.1 pg/mL, P = .02, respectively). Left ventricular ejection fraction at 12 months correlated inversely with BNP level at 12 months (r = −0.55, P = .001). Conclusions Carvedilol therapy is associated with a sustained decline in BNP and NANP levels. Serial BNP levels can provide some guidance regarding probability of LVEF improvement, but the relationship is not strong enough for BNP levels to supplant measurement of LVEF.